The TRAMPOLINE VT Study
Research type
Research Study
Full title
Critical Arrhythmogenic Sites In Human Ventricular Tachycardia: Mechanistic Insights And Determinants Of Clinical Outcomes From Non-Invasive Imaging And Ultra-High Density Activation Mapping
IRAS ID
293735
Contact name
Pier Lambiase
Contact email
Sponsor organisation
Queen Mary University of London
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 5 months, 30 days
Research summary
People who have a weakened heart muscle – like those who have survived a heart attack or have a heart muscle disorder (cardiomyopathy) – are at risk of developing dangerous heart rhythms. These dangerous rhythms are known as ventricular tachycardia (VT) and ventricular fibrillation (VF), and they cause the heart to beat extremely fast. If VT or VF is not treated urgently (usually with an electrical shock known as ‘defibrillation’), this can be fatal. In the last few decades we have learnt to implant people at risk of these rhythms with internal cardioverter defibrillators (ICDs). These devices monitor the heart and deliver electrical shocks which can stop VT/VF, however the shocks are very unpleasant. \n\nTo try and prevent repeated episodes of VT/VF, we can perform an ablation procedure using wires inside the heart which burn away the source of these rhythms. Unfortunately, long term success rates for VT ablation are currently only moderate (about 50% effective). By combining data from MRI scans with new technology that creates more accurate electrical maps inside the heart, this project seeks to improve VT ablation accuracy and success rates, and will discover more about the mechanisms which cause this important arrhythmia.
REC name
South West - Frenchay Research Ethics Committee
REC reference
22/SW/0109
Date of REC Opinion
8 Sep 2022
REC opinion
Further Information Favourable Opinion